Colon Cancer Biomarkers: Implications for Personalized Medicine
Abstract
:1. Cancers at Different Anatomical Sites Display Different Predictive Biomarkers but the Significance of Molecular Subtyping in Improving Colon Cancer Survival Remains to Be Demonstrated
2. Limited Efficacy to Date of Molecular Target-Based Therapies in Colorectal Cancer
3. Lack of Success of “Tumor Agnostic Molecular Therapies” for Colorectal Cancer
4. Differential Selection Criteria Should Apply for Screening and Prognostic Markers Compared to Predictive Biomarkers
5. Opportunity to Combine Colorectal Biomarkers from Different Classes as Personalized Medicine “Prognostic Signatures”
6. Improving Predictive Biomarkers by Improving Sample Accession Techniques
7. Predictive Markers Need to Be Performed Immediately before Therapy Selection
Funding
Acknowledgments
Conflicts of Interest
References
- Pritzker, K.P.H. Cancer biomarkers: Easier said than done. Clin. Chem. 2002, 48, 1147–1150. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pritzker, L.B.; Pritzker, K.P.H. Molecular Signatures as Cancer Biomarkers: Methodologic Issues in Discovery, Validation, Qualification, and Standardization. In Field Cancerization: Basic Science and Clinical Applications; Dakubo, G., Ed.; Nova Publishers: Hauppauge, NJ, USA, 2011; pp. 537–557. [Google Scholar]
- Pritzker, K.P. Predictive and prognostic cancer biomarkers revisited. Exp. Rev. Mol. Diagn. 2015, 1–4. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pritzker, K.P.; Azad, A. Genomic biomarkers for cancer assessment: Implementation challenges for laboratory practice. ClinBiochem 2004, 37, 642–646. [Google Scholar] [CrossRef] [PubMed]
- Monzon, F.A.; Ogino, S.; Hammond, M.E.; Halling, K.C.; Bloom, K.J.; Nikiforova, M.N.; Monzon, F.A.; Ogino, S.; Hammond, M.E.H.; Halling, K.C.; et al. The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer. Arch. Pathol. Lab. Med. 2009, 133, 1600–1606. [Google Scholar] [PubMed]
- Pander, J.; Gelderblom, H.; Antonini, N.F.; Tol, J.; van Krieken, J.H.; van der Straaten, T.; Punt, C.J.; Guchelaar, H.J. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur. J. Cancer 2010, 46, 1829–1834. [Google Scholar] [CrossRef]
- Cherny, N.I.; de Vries, E.G.; Emanuel, L.; Fallowfield, L.; Francis, P.A.; Gabizon, A.; Piccart, M.J.; Sidransky, D.; Soussan-Gutman, L.; Tziraki, C. Words matter: Distinguishing “personalized medicine” and “biologicallypersonalized therapeutics”. J. Natl. Cancer Inst. 2014, 106. [Google Scholar] [CrossRef]
- Boussios, S.; Ozturk, M.A.; Moschetta, M.; Karathanasi, A.; Zakynthinakis-Kyriakou, N.; Katsanos, K.H.; Christodoulou, D.K.; Pavlidis, N. The Developing Story of Predictive Biomarkers in Colorectal Cancer. J. Pers. Med. 2019, 9, 12. [Google Scholar] [CrossRef] [Green Version]
- Stintzing, S.; Tejpar, S.; Gibbs, P.; Thiebach, L.; Lenz, H.-J. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur. J. Cancer 2017, 84, 69–80. [Google Scholar] [CrossRef] [Green Version]
- Kaz, A.M.; Wong, C.J.; Dzieciatkowski, S.; Luo, Y.; Schoen, R.E.; Grady, W.M. Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics 2014, 9, 492–502. [Google Scholar] [CrossRef] [Green Version]
- Missiaglia, E.; Jacobs, B.; D’Ario, G.; Di Narzo, A.; Soneson, C.; Budinska, E.; Popovici, V.; Vecchione, L.; Gerster, S.; Yan, P.; et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 2014, 25, 1995–2001. [Google Scholar] [CrossRef]
- Phipps, A.I.; Limburg, P.J.; Baron, J.A.; Burnett-Hartman, A.N.; Weisenberger, D.J.; Laird, P.W.; Sinicrope, F.A.; Rosty, C.; Buchanan, D.D.; Potter, J.D.; et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2014, 148, 77–87.e2. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alwers, E.; Jia, M.; Kloor, M.; Bläker, H.; Brenner, H.; Hoffmeister, M. Associations between Molecular Classifications of Colorectal Cancer and Patient Survival: A Systematic Review. Clin. Gastroenterol. Hepatol. 2019, 17, 402–410.e2. [Google Scholar] [CrossRef] [PubMed]
- Jørgensen, J.T. Site-agnostic biomarker-guided oncology drug development. Expert Rev. Mol. Diagn. 2019, 20, 583–592. [Google Scholar] [CrossRef] [PubMed]
- Molnar, B.; Toth, K.; Bartak, B.K.; Tulassay, Z. Plasma methylated septin 9: A colorectal cancer screening marker. Exp. Rev. Mol. Diagn. 2015, 15, 171–184. [Google Scholar] [CrossRef] [PubMed]
- Qaseem, A.; Crandall, C.J.; Mustafa, R.A.; Hicks, L.A.; Wilt, T.J. Clinical Guidelines Committee of the American College of P: Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement from the American College of Physicians. Ann. Int. Med. 2019, 171, 643–654. [Google Scholar] [CrossRef] [Green Version]
- Sanchez-Ibarra, H.E.; Jiang, X.; Gallegos-Gonzalez, E.Y.; Cavazos-González, A.C.; Chen, Y.; Morcos, F.; Barrera-Saldaña, H.A. KRAS, NRAS, and BRAF mutation prevalence, clinicopathological association, and their application in a predictive model in Mexican patients with metastatic colorectal cancer: A retrospective cohort study. PLoS ONE 2020, 15, e0235490. [Google Scholar] [CrossRef] [PubMed]
- Mori, Y.; Kudo, S.-E.; Misawa, M.; Takeda, K.; Kudo, T.; Itoh, H.; Oda, M.; Mori, K. How Far Will Clinical Application of AI Applications Advance for Colorectal Cancer Diagnosis? J. Anus Rectum Colon. 2020, 4, 47–50. [Google Scholar] [CrossRef]
- Thakur, N.; Yoon, H.; Chong, Y. Current Trends of Artificial Intelligence for Colorectal Cancer Pathology Image Analysis: A Systematic Review. Cancers 2020, 12, 1884. [Google Scholar] [CrossRef]
- Fujiyoshi, K.; Vayrynen, J.P.; Borowsky, J.; Papke, D.J., Jr.; Arima, K.; Haruki, K.; Kishikawa, J.; Akimoto, N.; Ugai, T.; Lau, M.C.; et al. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer. EBioMedicine 2020, 57, 102860. [Google Scholar] [CrossRef] [PubMed]
- Zhavoronkov, A. Artificial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel Chemistry. Mol. Pharm. 2018, 15, 4311–4313. [Google Scholar] [CrossRef] [Green Version]
- Allegra, C.J.; Jessup, J.M.; Somerfield, M.R.; Hamilton, S.R.; Hammond, E.H.; Hayes, D.F.; McAllister, P.K.; Morton, R.F.; Schilsky, R.L. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. J. Clin. Oncol. 2009, 27, 2091–2096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lieberman, R. Personalized Medicine Enters the US Marketplace: KRAS, Anti-EGFR Monoclonal Antibodies, and Colon Cancer. Am. J. Ther. 2009, 16, 477–479. [Google Scholar] [CrossRef] [PubMed]
- Pritzker, K.P.H.; Nieminen, H.J. Needle Biopsy Adequacy in the Era of Precision Medicine and Value-Based Health Care. Arch. Pathol. Lab. Med. 2019, 143, 1399–1415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Najafi, M.; Farhood, B.; Mortezaee, K. Cancer stem cells (CSCs) in cancer progression and therapy. J. Cell. Physiol. 2019, 234, 8381–8395. [Google Scholar] [CrossRef]
- Jahanafrooz, Z.; Mosafer, J.; Akbari, M.; Hashemzaei, M.; Mokhtarzadeh, A.; Baradaran, B. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. J. Cell. Physiol. 2019, 235, 4153–4166. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pritzker, K.P.H. Colon Cancer Biomarkers: Implications for Personalized Medicine. J. Pers. Med. 2020, 10, 167. https://doi.org/10.3390/jpm10040167
Pritzker KPH. Colon Cancer Biomarkers: Implications for Personalized Medicine. Journal of Personalized Medicine. 2020; 10(4):167. https://doi.org/10.3390/jpm10040167
Chicago/Turabian StylePritzker, Kenneth P.H. 2020. "Colon Cancer Biomarkers: Implications for Personalized Medicine" Journal of Personalized Medicine 10, no. 4: 167. https://doi.org/10.3390/jpm10040167